Abstract
Purpose: Early detection and control of inflammation are important to manage Graves’ orbitopathy (GO). We investigated the effects of calprotectin (S100A8/A9) on orbital fibroblast inflammation and GO pathogenesis. Methods: We measured serum calprotectin, S100A8 and S100A9 mRNA expression in orbital fat/connective tissue from GO patients and healthy controls, and proinflammatory cytokines in primary cultured orbital fibroblasts. Results: The serum levels of S100A8/A9 and the expression of S100A8/A9 mRNA in orbital tissue were higher in the GO patients than in the healthy controls. The serum calprotectin levels positively correlated with the clinical activity score and serum thyroid-stimulating immunoglobulin levels. In cultured GO orbital fibroblasts, S100A8/A9 increased the expression of interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1, as well as the phosphorylation of extracellular signal-regulated kinase and nuclear factor-κB. Conclusion: We demonstrated the potential of calprotectin as a biomarker of GO severity and proinflammatory responses to S100A8/A9 in GO orbital fibroblasts.
| Original language | English |
|---|---|
| Journal | Ocular Immunology and Inflammation |
| DOIs | |
| Publication status | Accepted/In press - 2018 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Ophthalmology
Cite this
}
Proinflammatory Effects of Calprotectin in Graves’ Orbitopathy. / Kim, Ji Won; Ko, Jae Sang; Kim, Jin Joo; Yoon, Jinsook.
In: Ocular Immunology and Inflammation, 01.01.2018.Research output: Contribution to journal › Article
TY - JOUR
T1 - Proinflammatory Effects of Calprotectin in Graves’ Orbitopathy
AU - Kim, Ji Won
AU - Ko, Jae Sang
AU - Kim, Jin Joo
AU - Yoon, Jinsook
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose: Early detection and control of inflammation are important to manage Graves’ orbitopathy (GO). We investigated the effects of calprotectin (S100A8/A9) on orbital fibroblast inflammation and GO pathogenesis. Methods: We measured serum calprotectin, S100A8 and S100A9 mRNA expression in orbital fat/connective tissue from GO patients and healthy controls, and proinflammatory cytokines in primary cultured orbital fibroblasts. Results: The serum levels of S100A8/A9 and the expression of S100A8/A9 mRNA in orbital tissue were higher in the GO patients than in the healthy controls. The serum calprotectin levels positively correlated with the clinical activity score and serum thyroid-stimulating immunoglobulin levels. In cultured GO orbital fibroblasts, S100A8/A9 increased the expression of interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1, as well as the phosphorylation of extracellular signal-regulated kinase and nuclear factor-κB. Conclusion: We demonstrated the potential of calprotectin as a biomarker of GO severity and proinflammatory responses to S100A8/A9 in GO orbital fibroblasts.
AB - Purpose: Early detection and control of inflammation are important to manage Graves’ orbitopathy (GO). We investigated the effects of calprotectin (S100A8/A9) on orbital fibroblast inflammation and GO pathogenesis. Methods: We measured serum calprotectin, S100A8 and S100A9 mRNA expression in orbital fat/connective tissue from GO patients and healthy controls, and proinflammatory cytokines in primary cultured orbital fibroblasts. Results: The serum levels of S100A8/A9 and the expression of S100A8/A9 mRNA in orbital tissue were higher in the GO patients than in the healthy controls. The serum calprotectin levels positively correlated with the clinical activity score and serum thyroid-stimulating immunoglobulin levels. In cultured GO orbital fibroblasts, S100A8/A9 increased the expression of interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1, as well as the phosphorylation of extracellular signal-regulated kinase and nuclear factor-κB. Conclusion: We demonstrated the potential of calprotectin as a biomarker of GO severity and proinflammatory responses to S100A8/A9 in GO orbital fibroblasts.
UR - http://www.scopus.com/inward/record.url?scp=85057561030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057561030&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1547835
DO - 10.1080/09273948.2018.1547835
M3 - Article
AN - SCOPUS:85057561030
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
SN - 0927-3948
ER -